Immix Biopharma, Inc.
Clinical-stage biopharma developing cell therapies and addressing CAR-T neurotoxicity.
IMMX | US
Overview
Corporate Details
- ISIN(s):
- US45258H1068
- LEI:
- Country:
- United States of America
- Address:
- 11400 WEST OLYMPIC BLVD., 90064 LOS ANGELES
- Website:
- https://immixbio.com/
- Sector:
- Manufacturing
Description
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for serious diseases. The company's primary strategy is to advance Chimeric Antigen Receptor T-cell (CAR-T) therapies by addressing their key limitation: neurotoxicity. By working to overcome this side effect, ImmixBio aims to expand the use of CAR-T treatments to a wider range of patients, medical centers, and new indications, with a lead program targeting AL Amyloidosis. The company is also developing a novel class of Tissue-Specific Therapeutics (TSTx) for applications in oncology and inflammation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immix Biopharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immix Biopharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immix Biopharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
